Phase 1 Clinical Study of JTZ-951 - Clinical Pharmacology study

Japan Tobacco Inc.0 个研究点目标入组 6 人开始时间: 2012年9月24日最近更新: 2023年10月17日

适应症

试验速览

阶段: 1 期
状态: 已完成
发起方: Japan Tobacco Inc.
入组人数: 6

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

After single oral dose administration of JTZ-951 in CKD patients receiving maintenance hemodialysis, JTZ-951 was absorbed rapidly and the plasma concentration declined in a biphasic manner. Single-dose administration of JTZ-951 was well tolerated.

研究设计

研究类型: Interventional

入排标准

年龄范围: >= 20age old 至 <= 74age old（—）
性别: All

入选标准

•Patients undergoing hemodialysis consistently 3 times weekly
•-Dry weight between 35kg and 70kg

排除标准

•-Systolic blood pressure of 180 mmHg or more and diastolic blood pressure of 110 mmHg or more
•-Patients with congestive heart failure
•-Patients with malignancy

研究者

发起方

Japan Tobacco Inc.

相似试验

已完成

2 期

An Early Phase 2 Study of JTZ-951 in Anemic Patients with Chronic Kidney Disease Receiving Maintenance Hemodialysis <Anemia Correction study>Anemia with CKD

JPRN-jRCT2080222207Japan Tobacco Inc.40

已完成

2 期

An Early Phase 2 Study of JTZ-951 in Anemic Patients with Chronic Kidney Disease Not Requiring Dialysis <Anemia Correction study>Anemia with CKD

JPRN-jRCT2080222246Japan Tobacco Inc.22

已完成

1 期

Pharmacokinetics and Safety Study of YZJ-1139 in Subjects With Severe Renal Impairment and Normal Renal ImpairmentRenal ImpairmentInsomnia

NCT06671444Shanghai Haiyan Pharmaceutical Technology Co., Ltd.16

已完成

2 期

ate Phase 2 Study of JTZ-951 in Anemic Patients with Chronic Kidney Disease Receiving Maintenance Hemodialysis <Anemia Correction / Maintenance Study>Anemia with CKD

JPRN-jRCT2080222839Japan Tobacco Inc.71

已完成

2 期

ate Phase 2 Study of JTZ-951 in Anemic Patients with Chronic Kidney Disease Not Requiring Dialysis <Anemia Correction / Switch / Maintenance Study>Anemia with CKD

JPRN-jRCT2080222829Japan Tobacco Inc.201